Phase Forward to Acquire Maaguzi for $11M, Profits Down in Q2

Tuesday, July 28, 2009 03:09 PM

Within days of announcing the pending acquisition of Covance’s interactive voice and web response business, eClinical company Phase Forward announced Monday it has purchased technology company Maaguzi for $11 million cash.

With operations in Indianapolis, Ind., and Morrisville, N.C., Maaguzi provides electronic patient reported outcomes (ePRO) services to the pharmaceutical industry. The acquisition of Maaguzi's lead technology, OutcomeLogix, facilitates Phase Forward’s entry into the ePRO and observational studies market. Maaguzi’s chief operating officer Scott Dixon will join Phase Forward as vice president of its newly formed Outcome Logix Group.

“We believe our recent acquisitions are critical steps to ensuring that Phase Forward maintains and extends its current leadership position,” Phase Forward chairman and CEO Bob Weiler told investors on a conference call last night.

The Waltham, Mass.-based company also reported financial results for the second quarter of 2009, reflecting a $1.5-million decrease in net income. GAAP net income for the quarter was $2.2 million, or $0.05 per diluted share, compared with $3.7 million, or $0.08 per diluted share in 2008. Q2 revenues were up 29% to $52.5 million, compared with revenues of $40.9 million in the second quarter of 2008.

Phase Forward's shares were down 9% to $14.27 in afternoon trading Tuesday.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs